Biblio Discovery — Demo Discovery Service

25 hasil untuk "Alessandro Cellini"

Menampilkan 1–20 · 1,24 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Structural Damage Assessment of an Airfoil Anti-Icing System under Hailstorm Conditions

    Carlo Giovanni Ferro; Alessandro Cellini; Paolo Maggiore

    Aerospace, Vol. 11 No. 7 · 2024 · Inggris · DOAJ Scopus

    This paper presents a comprehensive comparative study of the resilience of leading edge anti-icing systems on business jets when exposed to severe hailstorm conditions. Using advanced simulation models correlated with experimental data, the study aims to determine the overall effectiveness of these…

  2. Artikel Jurnal Teks lengkap

    Demyelinating Polyradiculoneuropathy in Chronic Lymphocytic Leukemia: A Case Report on BTKis versus Venetoclax-Rituximab

    Alessandro Cellini; Andrea Visentin; Alessandro Salvalaggio dkk.

    Hemato, Vol. 5 No. 1 · 2023 · Inggris · DOAJ Scopus

    The dysregulation of the immune system in Chronic Lymphocytic Leukemia (CLL) often allows for the development of immune-mediated diseases. Among them, autoimmune cytopenias are the most common, but cases of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been reported. We…

  3. Artikel Jurnal

    Case Report: Triplet combination with pirtobrutinib/venetoclax/rituximab in accelerated phase of chronic lymphocytic leukemia

    Andrea Serafin; Alessandro Cellini; Francesco Angotzi dkk.

    Frontiers in Hematology, Vol. 4 · 2025 · Inggris · DOAJ Scopus

    The management of accelerated chronic lymphocytic leukemia (A-CLL), an aggressive and rare variant of CLL characterized by increased proliferation and histologically defined features, remains a challenging area with limited evidence. A-CLL is distinguished by its intermediate behavior between…

  4. Artikel Jurnal Teks lengkap

    A Case of Hemophagocytic Lymphohistiocytosis Triggered by Disseminated Tuberculosis and Hairy Cell Leukaemia after SARS-CoV2 Infection

    Alessandro Cellini; Andrea Visentin; Massimiliano Arangio Febbo dkk.

    Applied Sciences, Vol. 12 No. 2 · 2022 · Inggris · DOAJ Scopus

    Hemophagocytic Lymphohistiocytosis (HLH) is a rare but life-threatening disease that can occur either as a primary condition or as a consequence of a variety of triggers, including infectious diseases. Here we present a case of secondary HLH triggered by systemic Mycobacterium tuberculosis…

  5. Artikel Jurnal

    Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells

    Alessandro Cellini; Federico Scarmozzino; Francesco Angotzi dkk.

    Frontiers in Oncology, Vol. 13 · 2023 · Inggris · DOAJ Scopus

    Immune evasion is considered one of the modern hallmarks of cancer and is a key element in the pathogenesis of classical Hodgkin Lymphoma (cHL). This haematological cancer achieves effective avoidance of the host’s immune system by overexpressing the PD-L1 and PD-L2 proteins on the surface of the…

  6. Artikel Jurnal Teks lengkap

    Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases

    Francesco Angotzi; Andrea Visentin; Federico Scarmozzino dkk.

    Current Oncology, Vol. 29 No. 3 · 2022 · Inggris · DOAJ Scopus

    The disease course of chronic lymphocytic leukemia (CLL) is frequently characterized by the occurrence of various complications, such as second primary cancer, which can impact patients’ prognoses. While therapies for CLL have evolved tremendously in the past decades, overlooking the possibility of…

  7. Artikel Jurnal

    Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience

    Mattia D’Antiga; Nicolò Danesin; Giovanni Leone dkk.

    Annals of Hematology, Vol. 105 No. 3 · 2026 · Inggris · DOAJ Scopus

    Abstract Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL) in Western countries, with 65 beign the average age at diagnosis [1]. First-line treatment regimens combining Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) have shown favorable outcomes in pivotal…

  8. Artikel Jurnal

    Right atrial thrombus in treatment-naive patient with an early-stage classical Hodgkin lymphoma: a case report and review of the literature

    Anna Giordano; Valentina Bodanza; Francesco Angotzi dkk.

    Frontiers in Hematology, Vol. 5 · 2026 · Inggris · DOAJ Scopus

    Patients with hematologic malignancies are at increased risk of thrombotic complications, which most commonly occur during chemotherapy or in association with central venous catheter placement. Thrombotic events detected before systemic treatment initiation are uncommon, and intracardiac thrombosis…

  9. Artikel Jurnal

    Outcomes of patients with CLL and borderline IGHV mutational status: a systematic review and meta analysis

    Francesco Angotzi; Arianna Bevilacqua; Andrea Serafin dkk.

    Biomarker Research, Vol. 14 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract The immunoglobulin heavy chain variable region (IGHV) mutational status is a major prognostic factor in chronic lymphocytic leukemia (CLL). While patients are conventionally classified as mutated (M-IGHV) or unmutated (U-IGHV) using a 98% germline identity cutoff, increasing interest has…

  10. Artikel Jurnal Teks lengkap

    A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency

    Andrea Visentin; Maria Chiara Molinari; Stefano Pravato dkk.

    Current Oncology, Vol. 30 No. 1 · 2022 · Inggris · DOAJ Scopus

    Secondary antibody deficiency (SAD) is a common complication in chronic lymphocytic leukemia (CLL) which favors the development of life-threatening infections. Subcutaneous immunoglobulins (IG) (SCIG) have been proven to be as effective as intravenous immunoglobulin (IVIG) in primary…

  11. Artikel Jurnal

    Focal adhesion kinase FAK interplays with ROR1 in the aggressiveness of chronic lymphocytic leukemia

    Maria Castronuovo; Guido Capasso; Allison Beltrame dkk.

    BMC Medicine, Vol. 24 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract Background In chronic lymphocytic leukemia (CLL), B-cell receptor, chemokine receptor and integrin signaling contribute to disease progression by influencing cell survival, migration and microenvironment interactions. Focal adhesion kinase (FAK) has recently been involved in these disease…

  12. Artikel Jurnal

    Prognostic and predictive impact of NOTCH1 mutations in patients with chronic lymphocytic leukemia: a tertiary single-center experience

    Mattia D’Antiga; Andrea Serafin; Francesco Angotzi dkk.

    Frontiers in Oncology, Vol. 15 · 2026 · Inggris · DOAJ Scopus

    NOTCH1 mutations (NOTCH1m) occur in 6%–12% of newly diagnosed chronic lymphocytic leukemia (CLL) patients, increasing to 15%–20% in relapsed cases. Despite their clinical relevance, the independent prognostic impact of NOTCH1m remains controversial, particularly in the era of targeted therapies…

  13. Artikel Jurnal

    Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD

    Alessandro Cellini; Chiara Adele Cavarretta; Francesco Angotzi dkk.

    Frontiers in Oncology, Vol. 14 · 2024 · Inggris · DOAJ Scopus

    IntroductionThe identification of baseline prognostic factors in Classical Hodgkin Lymphoma could help in tailoring a risk-based approach as the therapeutic landscape expands. Currently, the International Prognostic Score (IPS) represents the most used prediction tool in clinical practice, but…

  14. Artikel Jurnal

    Extent of bone marrow infiltration predicts disease progression in asymptomatic Waldenström macroglobulinemia

    Nicolò Danesin; Giovanni Leone; Mattia D’Antiga dkk.

    Discover Oncology, Vol. 17 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract While data suggest that bone marrow (BM) disease burden in asymptomatic Waldenström Macroglobulinemia (WM) may be related to time to progression, no consensus has yet been reached regarding the optimal thresholds. A 25% BM infiltration threshold was used to stratify our cohort of 150…

  15. Artikel Jurnal

    Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy

    Edoardo Ruggeri; Federica Frezzato; Nayla Mouawad dkk.

    Frontiers in Immunology, Vol. 15 · 2024 · Inggris · DOAJ Scopus

    IntroductionIn classical Hodgkin lymphoma (cHL), the survival of neoplastic cells is mediated by the activation of NF-κB, JAK/STAT and PI3K/Akt signaling pathways. CK2 is a highly conserved serine/threonine kinase, consisting of two catalytic (α) and two regulatory (β) subunits, which is involved…

  16. Artikel Jurnal

    Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro‐HL multicenter study

    Giovanni Manfredi Assanto; Eleonora Alma; Alessandro Cellini dkk.

    HemaSphere, Vol. 9 No. 7 · 2025 · Inggris · DOAJ Scopus

    Abstract Thrombosis Lymphoma (ThroLy) and Khorana scores have been conceived to predict the thrombotic risk in oncohematologic patients. Currently, there is no univocal indication to perform thromboprophylaxis in classical Hodgkin lymphoma (cHL). We performed a retrospective study to validate…

  17. Artikel Jurnal

    Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies

    Francesco Angotzi; Marco Petrella; Tamara Berno dkk.

    Frontiers in Oncology, Vol. 13 · 2023 · Inggris · DOAJ Scopus

    The approved combination of Tixagevimab/Cilgavimab has been shown to decrease the rate of symptomatic SARS-CoV-2 infection in patients at increased risk of inadequate response to vaccination. However, Tixagevimab/Cilgavimab was tested in a few studies that included patients with hematological…